(Q37897477)

25 August 2017

1 reference

title

New era for drug discovery and development in renal disease (English)

1 reference

25 August 2017

1 reference

Toshio Miyata

1

1 reference

25 August 2017

Katsushi Kikuchi

series ordinal

2

1 reference

25 August 2017

Hideyasu Kiyomoto

series ordinal

3

1 reference

25 August 2017

Charles van Ypersele de Strihou

series ordinal

4

1 reference

25 August 2017

language of work or name

English

0 references

publication date

5 July 2011

1 reference

Nature Reviews Nephrology

25 August 2017

published in

1 reference

25 August 2017

volume

7

1 reference

25 August 2017

issue

8

1 reference

25 August 2017

page(s)

469-477

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneph.2011.84

25 August 2017

exact match

0 references

cites work

Drug repositioning: identifying and developing new uses for existing drugs

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Trends in development and approval times for new therapeutics in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Can the pharmaceutical industry reduce attrition rates?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

PhRMA survey on the conduct of first-in-human clinical trials under exploratory investigational new drug applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Impact of microdosing clinical study -- why necessary and how useful?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

A decade of fragment-based drug design: strategic advances and lessons learned

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

From fragment to clinical candidate--a historical perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

In silico pharmacology for drug discovery: applications to targets and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

The role of plasminogen activator inhibitor 1 in renal and cardiovascular diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Multifunctionality of PAI-1 in fibrogenesis: evidence from obstructive nephropathy in PAI-1-overexpressing mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Plasminogen activator inhibitor-1 is a significant determinant of renal injury in experimental crescentic glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Plasminogen activator inhibitor-1 deficiency retards diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

A mutant, noninhibitory plasminogen activator inhibitor type 1 decreases matrix accumulation in experimental glomerulonephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Inhibition of plasminogen activator inhibitor-1: its mechanism and effectiveness on coagulation and fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Ph4Dock: pharmacophore-based protein-ligand docking

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

A novel inhibitor of plasminogen activator inhibitor-1 provides antithrombotic benefits devoid of bleeding effect in nonhuman primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Diabetic nephropathy: a disorder of oxygen metabolism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Targeting HIF-1 for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Cell biology. How cells endure low oxygen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Oxygen sensing by HIF hydroxylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Role and regulation of prolyl hydroxylase domain proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Essential role for prolyl hydroxylase domain protein 2 in oxygen homeostasis of the adult vascular system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Oxidants in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Oxidative stress as a major culprit in kidney disease in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Effects of NXY-059 in experimental stroke: an individual animal meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Regulatory mechanisms controlling gene expression mediated by the antioxidant response element

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Molecular mechanisms activating the Nrf2-Keap1 pathway of antioxidant gene regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Reoxygenation-specific activation of the antioxidant transcription factor Nrf2 mediates cytoprotective gene expression in ischemia-reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Transcription factor Nrf2 is protective during ischemic and nephrotoxic acute kidney injury in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Role of NRF2 in protection against hyperoxic lung injury in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

A small-molecule-inducible Nrf2-mediated antioxidant response provides effective prophylaxis against cerebral ischemia in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Two-site substrate recognition model for the Keap1-Nrf2 system: a hinge and latch mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Regulatory and reimbursement challenges for molecular imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Initial evaluation of dynamic human imaging using 18F-FRP170 as a new PET tracer for imaging hypoxia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Adaptation to hypoxia in the diabetic rat kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Ethics at phase 0: clarifying the issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Nontraditional approaches to first-in-human studies to increase efficiency of drug development: will microdose studies make a significant impact?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Incorporating protein flexibility in structure-based drug discovery: using HIV-1 protease as a test case

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Expression of glomerular plasminogen activator inhibitor type 1 in glomerulonephritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

NXY-059 for the treatment of acute ischemic stroke

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

The transcription factor NRF2 protects against pulmonary fibrosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Nrf2 counteracts cholestatic liver injury via stimulation of hepatic defense systems

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Imaging of brain hypoxia in permanent and temporary middle cerebral artery occlusion in the rat using 18F-fluoromisonidazole and positron emission tomography: a pilot study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Novel biomarkers of acute kidney toxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2011.84

Imaging of ischemic but viable myocardium using a new 18F-labeled 2-nitroimidazole analog, 18F-FRP170.

31 March 2020

1 reference

12 December 2020

Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-deficient mice.

1 reference

12 December 2020

Progressive renal disease: the chronic hypoxia hypothesis

1 reference

12 December 2020

Plasminogen activator inhibitor 1 in renal fibrin deposits of human nephropathies

1 reference

12 December 2020

Monitoring kidney safety in drug development: emerging technologies and their implications.

1 reference

12 December 2020

International Conference on Harmonisation; Guidance on M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals; availability. Notice.

1 reference

12 December 2020

The localization of plasminogen activator inhibitor-1 in glomerular subepithelial deposits in membranous nephropathy

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2011.84

1 reference

25 August 2017

1 reference